In vitro activity of telavancin and occurrence of vancomycin heteroresistance in isolates from patients enrolled in phase 3 clinical trials of hospital-acquired pneumonia.

Abstract

In phase 3 studies of the efficacy of telavancin for the treatment of hospital-acquired pneumonia, 704 Gram-positive and 627 Gram-negative aerobic bacterial pathogens were obtained at baseline from 1503 patients. The majority of Gram-positive isolates (n = 650 [92%]) were Staphylococcus aureus, of which 410 (63%) were methicillin-resistant (MRSA). Of the MRSA isolates, 9.5% were identified as heterogeneous vancomycin-intermediate S. aureus. All Gram-positive isolates were inhibited by ≤1 μg/mL of telavancin.

• Authors: Kevin M Krause, Johanne Blais, Stacey R Lewis, Christopher S Lunde, Steven L Barriere, H David Friedland, Michael M Kitt, Bret M Benton
• Journal: Diagnostic microbiology and infectious disease (Diagn Microbiol Infect Dis) Vol. 74 Issue 4 Pg. 429-31 (Dec 2012) ISSN: 1879-0070 [Electronic] United States
• PMID: 23083812 (Publication Type: Journal Article)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Aminoglycosides
• Anti-Bacterial Agents
• Lipoglycopeptides
• telavancin

Topics

• Aminoglycosides (pharmacology)
• Anti-Bacterial Agents (pharmacology)
• Carrier State (microbiology)
• Clinical Trials, Phase III as Topic
• Humans
• Lipoglycopeptides
• Microbial Sensitivity Tests
• Staphylococcal Infections (microbiology)
• Staphylococcus aureus (drug effects, isolation & purification)
• Vancomycin Resistance